MedCap AB (publ) (MCAP) - Net Assets
Based on the latest financial reports, MedCap AB (publ) (MCAP) has net assets worth Skr1.46 Billion SEK (≈ $157.00 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.61 Billion ≈ $280.45 Million USD) and total liabilities (Skr1.15 Billion ≈ $123.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MedCap AB (publ) asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.46 Billion |
| % of Total Assets | 55.98% |
| Annual Growth Rate | 14.5% |
| 5-Year Change | 109.1% |
| 10-Year Change | 399.13% |
| Growth Volatility | 19.13 |
MedCap AB (publ) - Net Assets Trend (2007–2025)
This chart illustrates how MedCap AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore MedCap AB (publ) balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for MedCap AB (publ) (2007–2025)
The table below shows the annual net assets of MedCap AB (publ) from 2007 to 2025. For live valuation and market cap data, see MCAP stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.46 Billion ≈ $157.00 Million |
+13.25% |
| 2024-12-31 | Skr1.29 Billion ≈ $138.63 Million |
+25.42% |
| 2023-12-31 | Skr1.03 Billion ≈ $110.53 Million |
+19.61% |
| 2022-12-31 | Skr858.70 Million ≈ $92.41 Million |
+23.08% |
| 2021-12-31 | Skr697.70 Million ≈ $75.08 Million |
+15.90% |
| 2020-12-31 | Skr602.00 Million ≈ $64.78 Million |
+80.89% |
| 2019-12-31 | Skr332.80 Million ≈ $35.81 Million |
+21.55% |
| 2018-12-31 | Skr273.80 Million ≈ $29.47 Million |
+2.28% |
| 2017-12-31 | Skr267.70 Million ≈ $28.81 Million |
-8.41% |
| 2016-12-31 | Skr292.29 Million ≈ $31.45 Million |
-5.15% |
| 2015-12-31 | Skr308.15 Million ≈ $33.16 Million |
+9.81% |
| 2014-12-31 | Skr280.63 Million ≈ $30.20 Million |
+26.46% |
| 2013-12-31 | Skr221.92 Million ≈ $23.88 Million |
+13.53% |
| 2012-12-31 | Skr195.48 Million ≈ $21.04 Million |
+15.11% |
| 2011-12-31 | Skr169.82 Million ≈ $18.28 Million |
-5.65% |
| 2010-12-31 | Skr179.99 Million ≈ $19.37 Million |
+5.91% |
| 2009-12-31 | Skr169.94 Million ≈ $18.29 Million |
+26.71% |
| 2008-12-31 | Skr134.11 Million ≈ $14.43 Million |
+5.24% |
| 2007-12-31 | Skr127.44 Million ≈ $13.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MedCap AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 101304300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr978.30 Million | 67.37% |
| Common Stock | Skr6.03 Million | 0.42% |
| Other Components | Skr467.77 Million | 32.21% |
| Total Equity | Skr1.45 Billion | 100.00% |
MedCap AB (publ) Competitors by Market Cap
The table below lists competitors of MedCap AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhongzhu Medical Holdings Co Ltd
SHG:600568
|
$775.71 Million |
|
MIPS AB
ST:MIPS
|
$776.01 Million |
|
Feitian Technologies Co Ltd
SHE:300386
|
$776.29 Million |
|
Zhejiang MustangBattery Co.Ltd
SHG:605378
|
$776.34 Million |
|
Suzhou Tianwo Science and Technology Co Ltd
SHE:002564
|
$775.47 Million |
|
MBK Public Company Limited
BK:MBK-R
|
$775.40 Million |
|
Grendene S.A
SA:GRND3
|
$775.35 Million |
|
Karnov Group AB
ST:KAR
|
$775.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MedCap AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,282,000,000 to 1,452,100,000, a change of 170,100,000 (13.3%).
- Net income of 219,800,000 contributed positively to equity growth.
- Share repurchases of 26,100,000 reduced equity.
- New share issuances of 30,000,000 increased equity.
- Other comprehensive income decreased equity by 28,399,999.
- Other factors decreased equity by 25,200,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr219.80 Million | +15.14% |
| Share Repurchases | Skr26.10 Million | -1.8% |
| Share Issuances | Skr30.00 Million | +2.07% |
| Other Comprehensive Income | Skr-28.40 Million | -1.96% |
| Other Changes | Skr-25.20 Million | -1.74% |
| Total Change | Skr- | 13.27% |
Book Value vs Market Value Analysis
This analysis compares MedCap AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 43.46x to 4.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | Skr11.04 | Skr479.80 | x |
| 2008-12-31 | Skr10.97 | Skr479.80 | x |
| 2009-12-31 | Skr11.87 | Skr479.80 | x |
| 2010-12-31 | Skr12.70 | Skr479.80 | x |
| 2011-12-31 | Skr13.65 | Skr479.80 | x |
| 2012-12-31 | Skr15.29 | Skr479.80 | x |
| 2013-12-31 | Skr17.25 | Skr479.80 | x |
| 2014-12-31 | Skr19.82 | Skr479.80 | x |
| 2015-12-31 | Skr21.03 | Skr479.80 | x |
| 2016-12-31 | Skr20.21 | Skr479.80 | x |
| 2017-12-31 | Skr19.76 | Skr479.80 | x |
| 2018-12-31 | Skr20.21 | Skr479.80 | x |
| 2019-12-31 | Skr24.37 | Skr479.80 | x |
| 2020-12-31 | Skr41.49 | Skr479.80 | x |
| 2021-12-31 | Skr47.02 | Skr479.80 | x |
| 2022-12-31 | Skr57.83 | Skr479.80 | x |
| 2023-12-31 | Skr68.85 | Skr479.80 | x |
| 2024-12-31 | Skr86.47 | Skr479.80 | x |
| 2025-12-31 | Skr96.78 | Skr479.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MedCap AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.14%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.43%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 1.79x
- Recent ROE (15.14%) is above the historical average (7.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -6.06% | -4.09% | 0.97x | 1.53x | Skr-20.47 Million |
| 2008 | 0.09% | 0.06% | 0.93x | 1.57x | Skr-12.64 Million |
| 2009 | 4.20% | 2.24% | 0.85x | 2.21x | Skr-8.00 Million |
| 2010 | 9.08% | 4.28% | 1.02x | 2.08x | Skr-1.37 Million |
| 2011 | 6.68% | 3.18% | 1.08x | 1.94x | Skr-5.32 Million |
| 2012 | 9.24% | 4.90% | 0.96x | 1.97x | Skr-1.41 Million |
| 2013 | 10.82% | 2.74% | 1.37x | 2.88x | Skr1.71 Million |
| 2014 | 3.19% | 1.00% | 1.55x | 2.06x | Skr-18.16 Million |
| 2015 | 6.90% | 2.38% | 1.28x | 2.26x | Skr-8.73 Million |
| 2016 | 0.03% | 0.01% | 1.51x | 2.08x | Skr-27.02 Million |
| 2017 | 0.79% | 0.51% | 0.69x | 2.27x | Skr-24.38 Million |
| 2018 | 0.22% | 0.08% | 1.06x | 2.47x | Skr-26.53 Million |
| 2019 | 16.38% | 7.09% | 0.90x | 2.57x | Skr20.92 Million |
| 2020 | 10.22% | 7.45% | 0.76x | 1.82x | Skr1.33 Million |
| 2021 | 13.86% | 10.53% | 0.78x | 1.68x | Skr26.90 Million |
| 2022 | 13.73% | 10.58% | 0.78x | 1.67x | Skr31.97 Million |
| 2023 | 16.83% | 10.85% | 0.95x | 1.62x | Skr69.91 Million |
| 2024 | 16.18% | 11.48% | 0.91x | 1.55x | Skr79.20 Million |
| 2025 | 15.14% | 10.43% | 0.81x | 1.79x | Skr74.59 Million |
Industry Comparison
This section compares MedCap AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MedCap AB (publ) (MCAP) | Skr1.46 Billion | -6.06% | 0.79x | $775.50 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About MedCap AB (publ)
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more